FUROSEMIDE (furosemide) by R-Pharm US is clinical pharmacology investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. First approved in 1994.
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
Furosemide is a loop diuretic that inhibits sodium and chloride reabsorption primarily in the loop of Henle, proximal and distal tubules, making it one of the most potent diuretic agents available. It is indicated for management of edema associated with congestive heart failure, renal disease, and hepatic cirrhosis, as well as hypertension. The drug works through a unique site of action independent of carbonic anhydrase inhibition, resulting in rapid onset (5 minutes IV, somewhat later IM/oral) and peak effect within 30 minutes.
Product is in late-stage life cycle with LOE approaching; commercial team size likely stabilized or consolidating as generic competition intensifies.
CLINICAL PHARMACOLOGY Investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that furosemide inhibits primarily the reabsorption…
Worked on FUROSEMIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bumetanide vs. Furosemide in Cirrhosis
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers
A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on furosemide offers limited growth trajectory as a mature generic with approaching LOE; career value lies in mastering commoditized product management, payer negotiations, and cost optimization rather than clinical innovation. Roles tend to be transactional and focused on market share defense in a price-competitive environment.